• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺炎克雷伯菌分离株对碳青霉烯类药物敏感性降低的发生率及机制

Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates.

作者信息

Kim Soo-Young, Park Yeon-Joon, Yu Jin-Kyung, Kim Han Sik, Park Yong Sung, Yoon Jong-Bok, Yoo Jin-Young, Lee Kyungwon

机构信息

Department of Clinical Pathology, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital, Suwon 442-723, South Korea.

出版信息

Diagn Microbiol Infect Dis. 2007 Jan;57(1):85-91. doi: 10.1016/j.diagmicrobio.2006.05.008. Epub 2006 Jul 18.

DOI:10.1016/j.diagmicrobio.2006.05.008
PMID:16854555
Abstract

In this study, we examined the prevalence of and mechanisms of decreased susceptibility to either imipenem or meropenem in Klebsiella pneumoniae isolates. A total of 230 clinical isolates of K. pneumoniae were collected from 13 clinical laboratories from a nationwide distribution. The MICs of imipenem and meropenem were determined by the agar dilution method. To characterize the isolates with decreased susceptibility to carbapenems (MICs of >2 microg/mL), we performed polymerase chain reaction amplification of a variety of beta-lactamase genes, isoelectric focusing, and outer membrane profile analysis using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry. Three isolates (BD6, BD8, and KN16) exhibited decreased susceptibility to carbapenems with imipenem MICs of 1, 4, and 8 microg/mL and meropenem MICs of 4, 8, and 4, respectively. Isolate BD6 produced bla(TEM-1), bla(SHV-12), and bla(OXA-17); isolate BD8 produced bla(GES-3), bla(SHV-12), and bla(OXA-17); and isolate KN16 produced bla(TEM-11), bla(SHV-12), and bla(DHA-1). In all the 3 isolates, OmpK35 porin was not expressed, and in 1 isolate (KN16), OmpK36 was not expressed either. The prevalence of decreased susceptibility to carbapenems was low (1.3%), and none of them showed overt resistance to carbapenems. Decreased susceptibility to carbapenems can occur in K. pneumoniae when bla(GES-3), bla(TEM-11), bla(SHV-12), bla(OXA-17), and/or bla(DHA-1) are produced in combination with porin loss. In addition, to our knowledge, this is the 1st report of bla(OXA-17) in Enterobacteriaceae.

摘要

在本研究中,我们检测了肺炎克雷伯菌分离株对亚胺培南或美罗培南敏感性降低的发生率及机制。从全国分布的13个临床实验室收集了总共230株肺炎克雷伯菌临床分离株。采用琼脂稀释法测定亚胺培南和美罗培南的最低抑菌浓度(MIC)。为了鉴定对碳青霉烯类药物敏感性降低(MIC>2μg/mL)的分离株,我们进行了多种β-内酰胺酶基因的聚合酶链反应扩增、等电聚焦以及使用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳和质谱进行外膜图谱分析。三株分离株(BD6、BD8和KN16)对碳青霉烯类药物的敏感性降低,亚胺培南的MIC分别为1、4和8μg/mL,美罗培南的MIC分别为4、8和4μg/mL。分离株BD6产生bla(TEM-1)、bla(SHV-12)和bla(OXA-17);分离株BD8产生bla(GES-3)、bla(SHV-12)和bla(OXA-17);分离株KN16产生bla(TEM-11)、bla(SHV-12)和bla(DHA-1)。在所有这三株分离株中,OmpK35孔蛋白均未表达,并且在一株分离株(KN16)中,OmpK36也未表达。对碳青霉烯类药物敏感性降低的发生率较低(1.3%),并且它们均未表现出对碳青霉烯类药物的明显耐药性。当同时产生bla(GES-3)、bla(TEM-11)、bla(SHV-12)、bla(OXA-17)和/或bla(DHA-1)并伴有孔蛋白缺失时,肺炎克雷伯菌可能会出现对碳青霉烯类药物敏感性降低的情况。此外,据我们所知,这是肠杆菌科中bla(OXA-17)的首次报道。

相似文献

1
Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates.肺炎克雷伯菌分离株对碳青霉烯类药物敏感性降低的发生率及机制
Diagn Microbiol Infect Dis. 2007 Jan;57(1):85-91. doi: 10.1016/j.diagmicrobio.2006.05.008. Epub 2006 Jul 18.
2
Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss.肺炎克雷伯菌临床分离株中,质粒介导的CMY-2和DHA-1 β-内酰胺酶通过孔蛋白缺失共同介导亚胺培南敏感性降低。
Int J Antimicrob Agents. 2007 Feb;29(2):201-6. doi: 10.1016/j.ijantimicag.2006.09.006. Epub 2007 Jan 3.
3
Prevalence of decreased susceptibility to carbapenems among Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii and investigation of carbapenemases.粘质沙雷氏菌、阴沟肠杆菌和弗氏柠檬酸杆菌对碳青霉烯类药物敏感性降低的发生率及碳青霉烯酶的研究
Diagn Microbiol Infect Dis. 2005 Aug;52(4):331-6. doi: 10.1016/j.diagmicrobio.2005.04.012.
4
Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.氟氧头孢治疗的附带损害:肺炎克雷伯菌临床分离株中孔蛋白缺陷的体内发展以及blaDHA-1的获得导致对厄他培南耐药,该分离株产CTX-M-3和SHV-5β-内酰胺酶
J Antimicrob Chemother. 2007 Aug;60(2):410-3. doi: 10.1093/jac/dkm215. Epub 2007 Jun 18.
5
Molecular epidemiology and antimicrobial susceptibility of extended- and broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolated in Portugal.葡萄牙分离出的产超广谱β-内酰胺酶和广谱β-内酰胺酶肺炎克雷伯菌的分子流行病学及抗菌药敏性
Int J Antimicrob Agents. 2009 Jul;34(1):29-37. doi: 10.1016/j.ijantimicag.2008.11.014. Epub 2009 Mar 9.
6
Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results.检测肺炎克雷伯菌中产碳青霉烯酶的三叶形测试(改良 Hodge 测试):注意假阳性结果。
J Antimicrob Chemother. 2010 Feb;65(2):249-51. doi: 10.1093/jac/dkp431. Epub 2009 Dec 8.
7
Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1.携带blaVIM-1的肺炎克雷伯菌中碳青霉烯耐药水平多样性的来源
J Antimicrob Chemother. 2006 Sep;58(3):669-72. doi: 10.1093/jac/dkl302. Epub 2006 Jul 26.
8
Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey.希腊雅典blaVIM-1阳性肺炎克雷伯菌的持续流行:一项前瞻性调查。
J Antimicrob Chemother. 2008 Jan;61(1):59-63. doi: 10.1093/jac/dkm443. Epub 2007 Nov 13.
9
Carbapenem-nonsusceptible strains of Klebsiella pneumoniae producing SHV-5 and/or DHA-1 beta-lactamases in a Czech hospital.捷克一家医院中产 SHV-5 和/或 DHA-1 型β-内酰胺酶的耐碳青霉烯类肺炎克雷伯菌。
FEMS Microbiol Lett. 2010 Aug 1;309(1):62-70. doi: 10.1111/j.1574-6968.2010.02016.x. Epub 2010 May 17.
10
Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden.挪威和瑞典出现序列型258的克隆相关肺炎克雷伯菌分离株,这些分离株产生质粒介导的KPC碳青霉烯酶。
J Antimicrob Chemother. 2009 Apr;63(4):654-8. doi: 10.1093/jac/dkp018. Epub 2009 Feb 13.

引用本文的文献

1
Clonality, outer-membrane proteins profile and efflux pump in KPC- producing Enterobacter sp. in Brazil.巴西产KPC的肠杆菌属细菌的克隆性、外膜蛋白谱及外排泵
BMC Microbiol. 2017 Mar 17;17(1):69. doi: 10.1186/s12866-017-0970-1.
2
Detection and analysis of different interactions between resistance mechanisms and carbapenems in clinical isolates of Klebsiella pneumoniae.肺炎克雷伯菌临床分离株中耐药机制与碳青霉烯类药物不同相互作用的检测与分析
Braz J Microbiol. 2017 Jul-Sep;48(3):493-498. doi: 10.1016/j.bjm.2017.01.003. Epub 2017 Feb 9.
3
Epidemiology of Carbapenem Resistance among Multi-drug Resistant Enterobacteriaceae in Uganda.
乌干达多重耐药肠杆菌科细菌对碳青霉烯类耐药的流行病学研究
Br Microbiol Res J. 2015;8(2):418-423. doi: 10.9734/BMRJ/2015/17055. Epub 2015 May 2.
4
Detection of blaIMP4 and blaNDM1 harboring Klebsiella pneumoniae isolates in a university hospital in Malaysia.在马来西亚一家大学医院中对携带blaIMP4和blaNDM1的肺炎克雷伯菌分离株的检测。
Emerg Health Threats J. 2015 Mar 10;8:26011. doi: 10.3402/ehtj.v8.26011. eCollection 2015.
5
Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance.携带多个编码这种抗生素抗性基因的耐碳青霉烯类铜绿假单胞菌临床分离株的特征分析。
Ann Clin Microbiol Antimicrob. 2014 Sep 2;13:43. doi: 10.1186/s12941-014-0043-3.
6
Nosocomial clustering of NDM-1-producing Klebsiella pneumoniae sequence type 340 strains in four patients at a South Korean tertiary care hospital.韩国一家三级保健医院的 4 名患者中产 NDM-1 的肺炎克雷伯菌 340 序列型的医院内聚集。
J Clin Microbiol. 2012 Apr;50(4):1433-6. doi: 10.1128/JCM.06855-11. Epub 2012 Jan 18.
7
Characterization of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream isolates at a Taiwanese hospital: clinical impacts of lowered breakpoints for carbapenems.中文译文:台湾某医院耐碳青霉烯类肺炎克雷伯菌血流感染分离株的特征:碳青霉烯类药物折点降低的临床影响。
Eur J Clin Microbiol Infect Dis. 2012 Aug;31(8):1941-50. doi: 10.1007/s10096-011-1525-2. Epub 2012 Jan 18.
8
Mechanistic basis for the emergence of catalytic competence against carbapenem antibiotics by the GES family of beta-lactamases.β-内酰胺酶GES家族对碳青霉烯类抗生素产生催化活性的机制基础。
J Biol Chem. 2009 Oct 23;284(43):29509-13. doi: 10.1074/jbc.M109.011262. Epub 2009 Aug 5.
9
Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use.临床综述:权衡有效使用抗假单胞菌碳青霉烯类药物所涉及的治疗、安全及经济问题。
Crit Care. 2008;12(5):233. doi: 10.1186/cc6994. Epub 2008 Oct 29.
10
Doripenem: a review of its use in the treatment of bacterial infections.多利培南:其在治疗细菌感染中的应用综述
Drugs. 2008;68(14):2021-57. doi: 10.2165/00003495-200868140-00007.